Understanding Heart Failure With Mid-Range Ejection Fraction

JACC: Heart Failure

Volumn 4, Issue 6, 2016, Pages 473-476

  Lam, Carolyn S P ^a,b   Teng, Tiew Hwa Katherine ^a,c  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Ejection fraction; Heart failure; Precipitating factors

Indexed keywords

CANDESARTAN; SPIRONOLACTONE;

ANEMIA; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; EDITORIAL; HEART DISEASE; HEART FAILURE; HEART FAILURE WITH MID RANGE EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART FAILURE WITH REDUCTION EJECTION FRACTION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; INFLUENZA; KIDNEY FAILURE; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; HEART STROKE VOLUME;

HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84977120415     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.03.025     Document Type: Editorial

References (17)

1. Lam C.S., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 2014, 16:1049-1055.
2. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112:3738-3744.
3. Gottdiener J.S., McClelland R.L., Marshall R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002, 137:631-639.
4. He K.L., Burkhoff D., Leng W.X., et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol 2009, 103:845-851.
5. Cheng R.K., Cox M., Neely M.L., et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014, 168:721-730.
6. Kapoor J.R., Kapoor R., Ju C., et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. J Am Coll Cardiol HF 2016, 4:464-472.
7. Dharmarajan K., Hsieh A.F., Lin Z., et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013, 309:355-363.
8. Udell J.A., Farkouh M.E., Solomon S.D., Vardeny O. Does influenza vaccination influence cardiovascular complications?. Expert Rev Cardiovasc Ther 2015, 13:593-596.
9. Dunlay S.M., Roger V.L., Weston S.A., Jiang R., Redfield M.M. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012, 5:720-726.
10. Hwang S.J., Melenovsky V., Borlaug B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014, 63(25 Pt A):2817-2827.
11. Clarke C.L., Grunwald G.K., Allen L.A., et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 2013, 6:680-686.
12. Solomon S.D., Claggett B., Lewis E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016, 37:455-462.
13. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
14. Hogg K., McMurray J. The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev 2006, 11:141-146.
15. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013, 62:263-271.
16. van Empel V.P., Mariani J., Borlaug B.A., Kaye D.M. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc 2014, 3:e001293.
17. Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015, 131:550-559.